12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Epanova: Phase III data

Additional data from the double-blind, international Phase III EVOLVE trial in 399 patients with triglyceride levels of 500-2,000 mg/dL showed that once-daily 2 and 4 g Epanova non-significantly increased mean HDL-C from baseline to week 12 vs. control (4 g olive oil) (8% and 6%, respectively, vs. 2%). Low- and high dose Epanova...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >